#United States #VitaSmart #Bridge to Life #Boston, MA #Hope

Bridge to Life to Present Groundbreaking Research at 2026 American Transplant Congress

Bridge to Life™ Ltd., a leader in organ preservation and perfusion technologies, has announced significant presentations for the upcoming 2026 Annual Meeting of the American Transplant Congress (ATC) scheduled from June 20-24 in Boston, MA. Among the highlights will be oral presentations that align with the company’s commitment to advancing technologies that improve organ transplant viability.

Key Presentations and Their Impacts

The conference will feature several oral abstracts, including a Plenary Session aimed at exploration and discussion of impactful practices related to organ donation and transplantation. One of the prominent presentations will be titled "HOPE for Human Uterus Transplantation: Improved Preservation and Viability Assessment for Enhanced Donor Utilization" by Dr. Keyue Sun from the Cleveland Clinic. This session will take place on June 21 from 3:45 PM to 4:45 PM EDT.

The Hypothermic Oxygenated Perfusion (HOPE) technique is gaining attention. It promises improved organ viability during the transportation and preservation phases. The session is opportune not only for medical professionals who seek to increase donor organ matches but also for researchers dedicated to expanding the frontiers of transplantation science.

Further discussions will include Dr. F. Selin Yildirim's presentation on the predictive potential of donor serum in determining liver transplant outcomes, emphasizing the metabolic signatures associated with graft quality—an essential element for improving patient prognoses post-transplantation.

Another pivotal session by Dr. Koki Takase will compare hypothermic and normothermic machine perfusion techniques in human small intestine transplantation. Scheduled as a part of the Monday Plenary Session on June 22 from 8:15 AM to 9:15 AM, this presentation aims to assess and advocate for the quantifiable benefits of HOPE over traditional practices, showcasing how these methods may revolutionize small intestine transplantation.

Symposium Highlight: Transitioning from Theory to Practice

In addition to these presentations, Bridge to Life will be sponsoring a symposium titled "The Next Era of Machine Perfusion: From Evidence to Adoption in Clinical Practice" on June 22 at 7:00 AM EDT. This session will provide attendees with an integrative discussion on implementing new practices based on the latest clinical evidence surrounding the HOPE technique in liver transplantation.

Notable speakers include Dr. David Foley from the University of Wisconsin and Dr. Andrea Schlegel of the Cleveland Clinic, both of whom will delve into the practical implications of HOPE, its economic feasibility, and its long-term sustainability in modern transplantation programs.

A Commitment to Innovation

Bridge to Life Ltd. continues its role as a pioneer in organ preservation technologies. With products such as the VitaSmart™ Hypothermic Oxygenated Perfusion System at the forefront, the organization emphasizes the importance of rigorous research and clinical applicability. As transplant centers and organ procurement organizations globally seek methods to maximize the utility of available organs, the discussions at ATC 2026 could pave the way for future advancements.

As the world grapples with increasing demands for transplants, the insights generated from the 2026 Annual Meeting of the ATC could set new benchmarks in organ preservation and encourage further innovations. These sessions not only reflect the progress achieved but also ignite discussions essential to the evolution of transplant methodologies.

In conclusion, Bridge to Life’s presence at this prestigious meeting encapsulates a dedication to enhancing human health through relentless innovation and collaborative effort in organ transplantation efforts.